ATE386101T1 - Expressionsplasmide, durch einen osmb promoter reguliert - Google Patents

Expressionsplasmide, durch einen osmb promoter reguliert

Info

Publication number
ATE386101T1
ATE386101T1 AT95914162T AT95914162T ATE386101T1 AT E386101 T1 ATE386101 T1 AT E386101T1 AT 95914162 T AT95914162 T AT 95914162T AT 95914162 T AT95914162 T AT 95914162T AT E386101 T1 ATE386101 T1 AT E386101T1
Authority
AT
Austria
Prior art keywords
regulated
expression plasmids
osmb promoter
plasmids
osmb
Prior art date
Application number
AT95914162T
Other languages
English (en)
Inventor
Meir Fischer
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Application granted granted Critical
Publication of ATE386101T1 publication Critical patent/ATE386101T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT95914162T 1994-03-22 1995-03-22 Expressionsplasmide, durch einen osmb promoter reguliert ATE386101T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/216,851 US5795776A (en) 1994-03-22 1994-03-22 Expression plasmids regulated by an OSMB promoter

Publications (1)

Publication Number Publication Date
ATE386101T1 true ATE386101T1 (de) 2008-03-15

Family

ID=22808753

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914162T ATE386101T1 (de) 1994-03-22 1995-03-22 Expressionsplasmide, durch einen osmb promoter reguliert

Country Status (9)

Country Link
US (2) US5795776A (de)
EP (1) EP0764202B1 (de)
JP (2) JP3878207B2 (de)
AT (1) ATE386101T1 (de)
AU (1) AU2126695A (de)
DE (1) DE69535704T2 (de)
IL (1) IL113031A (de)
WO (1) WO1995025785A1 (de)
ZA (1) ZA952056B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7132510B2 (en) 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
US20050266009A1 (en) * 2003-06-30 2005-12-01 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
MX2007012548A (es) * 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
KR20080009111A (ko) * 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
KR101662917B1 (ko) * 2011-11-25 2016-10-06 서울대학교산학협력단 Ｂ형 간염 바이러스 유래 ｃｉｓ-작용 조절 엘리먼트 및 그 용도
KR102771842B1 (ko) 2015-11-27 2025-02-21 에보닉 오퍼레이션스 게엠베하 L-메티오닌을 제조하는 방법
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
JP7728880B2 (ja) 2021-04-01 2025-08-25 エボニック オペレーションズ ゲーエムベーハー Ｌ－グルホシネートおよびそのホスホエステルを産生するための酵素的方法
EP4105335A1 (de) 2021-06-16 2022-12-21 Evonik Operations GmbH Enzymatisches verfahren zur herstellung von l-glufosinat-p-alkylestern
EP4493709A1 (de) 2022-03-14 2025-01-22 Evonik Operations GmbH Enzymatisches verfahren zur herstellung von l-glufosinat p-estern
WO2023222227A1 (en) 2022-05-19 2023-11-23 Evonik Operations Gmbh Enzymatic method for producing l-glufosinate
WO2023222226A1 (en) 2022-05-19 2023-11-23 Evonik Operations Gmbh Enzymatic method for producing l-glufosinate
WO2023232225A1 (en) 2022-05-31 2023-12-07 Evonik Operations Gmbh Enzymatic method for the diastereoselective production of l-glufosinate p-esters
WO2024061456A1 (en) 2022-09-21 2024-03-28 Evonik Operations Gmbh Enzymatic method for producing l-glufosinate and its phosphoesters
CN119907861A (zh) 2022-09-21 2025-04-29 赢创运营有限公司 用于生产l-草铵膦及其磷酸脂的酶促催化方法
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
DK582381A (da) * 1981-01-02 1982-07-03 Univ New York Remkombinat plasmid til anvendelse ved bakteriel kloning
US4666836A (en) * 1981-01-02 1987-05-19 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4863855A (en) * 1982-05-14 1989-09-05 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4745069A (en) * 1982-05-25 1988-05-17 Eli Lilly And Company Cloning vectors for expression of exogenous protein
EP0095361B1 (de) * 1982-05-25 1989-07-26 Eli Lilly And Company Klonbildungsvektoren für die Expression von exogenem Protein
JPS59203495A (ja) * 1983-04-28 1984-11-17 Kyowa Hakko Kogyo Co Ltd 外来遺伝子の新規な発現方法
US4757013A (en) * 1983-07-25 1988-07-12 The Research Foundation Of State University Of New York Cloning vehicles for polypeptide expression in microbial hosts
US4643969A (en) * 1983-07-25 1987-02-17 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
DE3445517C2 (de) * 1984-12-13 1993-11-18 Ciba Geigy Für ein Hirudin-ähnliches Protein codierende DNA-Sequenz und Verfahren zur Herstellung eines Hirudin-ähnlichen Proteins
DK175535B1 (da) * 1987-03-04 2004-11-29 Daiichi Suntory Pharma Co Ltd Fremgangsmåde til fremstilling af et fysiologisk aktivt cysteinholdigt peptid
US5063158A (en) * 1987-11-09 1991-11-05 Eli Lilly And Company Recombinant DNA expression vector comprising both transcriptional and translational activating sequences
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface

Also Published As

Publication number Publication date
WO1995025785A1 (en) 1995-09-28
IL113031A (en) 2006-07-05
AU2126695A (en) 1995-10-09
JP2006068019A (ja) 2006-03-16
EP0764202A1 (de) 1997-03-26
EP0764202A4 (de) 1998-01-07
JP3878207B2 (ja) 2007-02-07
EP0764202B1 (de) 2008-02-13
ZA952056B (en) 1995-12-11
IL113031A0 (en) 1995-06-29
US5945304A (en) 1999-08-31
JPH10500565A (ja) 1998-01-20
US5795776A (en) 1998-08-18
DE69535704T2 (de) 2009-02-12
DE69535704D1 (de) 2008-03-27

Similar Documents

Publication Publication Date Title
DE69535704D1 (de) EXPRESSIONSPLASMIDE, DURCH EINEN osmB PROMOTER REGULIERT
AP8600035A0 (en) Hepatitis B surface antigen formed by recombinant DNA Techniques, vaccines, diagnostics, cell lines and methods of forming same.
AU2474892A (en) Highly stable recombinant yeasts for the production of recombinant proteins
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
DK0757717T3 (da) Papillomavirusvacciner
GB8610600D0 (en) Transformation of trichoderma
WO1989007136A3 (en) Modified hepatocytes and uses therefor
NO976045L (no) Cytokin som induserer apoptosis
OA08947A (en) Mammalian interleukin-4.
FI934135A0 (fi) Ett foerfarande foer framstaellning av heme-proteiner
GB2301363A (en) Human phosphodiesterase type ivc and its production and use
ATE364703T1 (de) Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
AU5233686A (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
DE68918673D1 (de) IgG-bindendes Protein H, kodierendes Gen dafür und Verfahren zu seiner Herstellung.
ES552431A0 (es) Procedimiento para preparar plasmidos de expresion prhw11 y prhw12
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
EP0422217A4 (en) Human recombinant placental ribonuclease inhibitor and method of production
NZ304789A (en) Genes encoding lymphocyte interferon regulatory factory (lsirf) polypeptides that are transcription factors and specific antibodies to them
DE3586580D1 (de) Zur wirksamen gen-expression faehiger vektor und verwendung desselben.
DK0575462T3 (da) Fremgangsmåde til fremstilling af chymosin
EP0165759A3 (de) Säugetierpromotoren verwendbar in Hefeexpression
DK0887404T3 (da) Gen, som bibringer selektiv proliferationsaktivitet
ATE52798T1 (de) Hepatitis-b-virus-gen enthaltendes rekombinantes plasmid, mit diesem rekombinanten plasmid transformierte hefe und herstellung von hepatitis-b-virus-oberflaechenantigen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties